NR1H4 and metabolic dysfunction-associated steatotic liver disease: Evidence that TMAO-induced liver damage is mediated through its inhibitory effect on FXR signaling is supported by a study by Miyata et al., which found that in FXR-null mice, the exogenous administration of TMAO did not worsen MASLD but even improved it, as it reduced hepatic bile acid and cholesterol levels through a direct, FXR-independent mechanism [96].